Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Tipo de estudo
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Cell Host Microbe ; 28(2): 273-284.e6, 2020 08 12.
Artigo em Inglês | MEDLINE | ID: mdl-32668218

RESUMO

The clinical spectra of irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) intersect to form a scantily defined overlap syndrome, termed pre-IBD. We show that increased Enterobacteriaceae and reduced Clostridia abundance distinguish the fecal microbiota of pre-IBD patients from IBS patients. A history of antibiotics in individuals consuming a high-fat diet was associated with the greatest risk for pre-IBD. Exposing mice to these risk factors resulted in conditions resembling pre-IBD and impaired mitochondrial bioenergetics in the colonic epithelium, which triggered dysbiosis. Restoring mitochondrial bioenergetics in the colonic epithelium with 5-amino salicylic acid, a PPAR-γ (peroxisome proliferator-activated receptor gamma) agonist that stimulates mitochondrial activity, ameliorated pre-IBD symptoms. As with patients, mice with pre-IBD exhibited notable expansions of Enterobacteriaceae that exacerbated low-grade mucosal inflammation, suggesting that remediating dysbiosis can alleviate inflammation. Thus, environmental risk factors cooperate to impair epithelial mitochondrial bioenergetics, thereby triggering microbiota disruptions that exacerbate inflammation and distinguish pre-IBD from IBS.


Assuntos
Antibacterianos/efeitos adversos , Dieta Hiperlipídica/efeitos adversos , Disbiose/patologia , Metabolismo Energético/fisiologia , Doenças Inflamatórias Intestinais/microbiologia , Síndrome do Intestino Irritável/microbiologia , Animais , Anti-Inflamatórios não Esteroides/uso terapêutico , Disbiose/induzido quimicamente , Enterobacteriaceae/crescimento & desenvolvimento , Microbioma Gastrointestinal , Humanos , Mucosa Intestinal/microbiologia , Mucosa Intestinal/patologia , Complexo Antígeno L1 Leucocitário/metabolismo , Mesalamina/uso terapêutico , Camundongos , Camundongos Endogâmicos C57BL , Mitocôndrias/metabolismo , PPAR gama/agonistas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA